JP2022534118A5 - - Google Patents
Info
- Publication number
- JP2022534118A5 JP2022534118A5 JP2021570824A JP2021570824A JP2022534118A5 JP 2022534118 A5 JP2022534118 A5 JP 2022534118A5 JP 2021570824 A JP2021570824 A JP 2021570824A JP 2021570824 A JP2021570824 A JP 2021570824A JP 2022534118 A5 JP2022534118 A5 JP 2022534118A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- fgfr3
- infigratinib
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962855277P | 2019-05-31 | 2019-05-31 | |
| US62/855,277 | 2019-05-31 | ||
| US201962906194P | 2019-09-26 | 2019-09-26 | |
| US62/906,194 | 2019-09-26 | ||
| PCT/US2020/035140 WO2020243442A1 (en) | 2019-05-31 | 2020-05-29 | Methods of treating urinary system cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022534118A JP2022534118A (ja) | 2022-07-27 |
| JP2022534118A5 true JP2022534118A5 (cg-RX-API-DMAC7.html) | 2023-05-19 |
Family
ID=73553913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021570824A Pending JP2022534118A (ja) | 2019-05-31 | 2020-05-29 | 泌尿器系がんを治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220233537A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3976833A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022534118A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220088830A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114207151A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020282816A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3141871A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL288408A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021014524A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12021552973A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202112932QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020243442A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3202267A1 (en) * | 2020-12-18 | 2022-06-23 | Riccardo Panicucci | Methods of treating achondroplasia |
| CN117982507A (zh) * | 2022-11-01 | 2024-05-07 | Qed医药股份有限公司 | 英菲格拉替尼在治疗胃癌和腺癌中的用途 |
| CN115785001B (zh) * | 2022-11-23 | 2023-09-15 | 斯坦德药典标准物质研发(湖北)有限公司 | 一种英菲格拉替尼的制备方法 |
| CN117558346B (zh) * | 2023-09-01 | 2024-12-03 | 上海仁东医学检验所有限公司 | Utuc分子分型及预后预测模型构建方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007067968A2 (en) * | 2005-12-08 | 2007-06-14 | Novartis Ag | Effects of inhibitors of fgfr3 on gene transcription |
| CA2898326C (en) * | 2013-01-18 | 2022-05-17 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| TWI541022B (zh) * | 2013-12-18 | 2016-07-11 | 應克隆公司 | 針對纖維母細胞生長因子受體-3(fgfr3)之化合物及治療方法 |
| CN103757026B (zh) * | 2013-12-20 | 2017-04-05 | 广州圣露生物技术有限公司 | FGFR2b胞外段的基因序列、多肽及其应用 |
| SG11201702381QA (en) * | 2014-09-26 | 2017-04-27 | Janssen Pharmaceutica Nv | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
| CN110785184A (zh) * | 2017-02-06 | 2020-02-11 | 雷尼尔医疗公司 | 用于治疗癌症的方法,组合物和试剂盒 |
| KR20250047324A (ko) * | 2017-08-07 | 2025-04-03 | 더 존스 홉킨스 유니버시티 | 암을 평가하고 치료하기 위한 방법 및 재료 |
| MA47408B1 (fr) * | 2017-12-20 | 2023-08-31 | Janssen Pharmaceutica Nv | Traitement du cancer |
-
2020
- 2020-05-29 CN CN202080053765.5A patent/CN114207151A/zh active Pending
- 2020-05-29 EP EP20815357.7A patent/EP3976833A4/en active Pending
- 2020-05-29 MX MX2021014524A patent/MX2021014524A/es unknown
- 2020-05-29 PH PH1/2021/552973A patent/PH12021552973A1/en unknown
- 2020-05-29 AU AU2020282816A patent/AU2020282816A1/en not_active Abandoned
- 2020-05-29 WO PCT/US2020/035140 patent/WO2020243442A1/en not_active Ceased
- 2020-05-29 JP JP2021570824A patent/JP2022534118A/ja active Pending
- 2020-05-29 US US17/613,652 patent/US20220233537A1/en not_active Abandoned
- 2020-05-29 KR KR1020217043300A patent/KR20220088830A/ko active Pending
- 2020-05-29 CA CA3141871A patent/CA3141871A1/en active Pending
- 2020-05-29 SG SG11202112932QA patent/SG11202112932QA/en unknown
-
2021
- 2021-11-25 IL IL288408A patent/IL288408A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024530310A (ja) | T細胞リンパ腫治療薬の調製におけるezh2阻害剤の使用 | |
| Spitler | A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. | |
| JP5952890B2 (ja) | 膵臓癌を治療するための医薬製剤 | |
| JP2019081792A5 (cg-RX-API-DMAC7.html) | ||
| Cho et al. | Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer | |
| JP6462147B2 (ja) | Hsp90阻害ペプチド結合体及びその腫瘍治療における応用 | |
| JP2023513704A5 (cg-RX-API-DMAC7.html) | ||
| CN111184863B (zh) | 酪氨酸激酶抑制剂、cdk4/6抑制剂、serd联合在制备治疗肿瘤的药物中的用途 | |
| WO2015185011A1 (zh) | 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 | |
| US20190175598A1 (en) | Combination therapies for the treatment of hepatocellular carcinoma | |
| TW201300107A (zh) | 組合療法 | |
| CN107308164A (zh) | 辅助癌症治疗的方法 | |
| BR112019015023A2 (pt) | Intensificadores de canibalismo celular para uso para sensibilizar tumores para terapia por radiação | |
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| TW202110454A (zh) | Cdk4/6抑制劑與vegfr抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| CN109303781A (zh) | 川穹嗪在制备治疗子宫内膜异位症的药物中的应用 | |
| ES2554332T3 (es) | Utilización de la bencidamina en el tratamiento de las enfermedades dependientes de p40 | |
| WO2023281413A1 (en) | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer | |
| CN112826820B (zh) | Nlrp3抑制剂及其应用 | |
| JP2025509613A5 (cg-RX-API-DMAC7.html) | ||
| CN109963847A (zh) | 治疗实体瘤的方法 | |
| CN111728960B (zh) | 富马酸比索洛尔联合多西他赛在制备抗肿瘤药物中的应用 | |
| CN111388665B (zh) | 一种治疗肿瘤的复合物及其制剂和用途 | |
| CN110339195A (zh) | 用于治疗胆管癌的喹啉衍生物 | |
| CN118354772A (zh) | 治疗头颈癌的方法 |